Qure.ai is a healthcare AI startup based in Mumbai, India, that builds AI tools for reading radiology scans such as head CT and chest X-rays for hospitals and clinicians.

This Startup Deep Dive explains what Qure.ai does, how it makes money, who backs it, how it compares with rivals and what could go wrong, using publicly available information. It is educational and not investment advice. Last updated: October 2026.

Qure.ai in Brief

• What it is: Qure.ai is an Indian Healthcare AI radiology company based in Mumbai.
• Who it serves: patients, doctors, hospitals, diagnostic centres, insurers and employers.
• Qure.ai makes qER, a head CT triage tool, and qXR, a chest X-ray product that screens for tuberculosis and other abnormalities.
• AI products made up roughly 87% of FY24 revenue, about Rs 123 crore.
• February 2020: reported $16 million round led by Sequoia India.
• Funding: Not disclosed in public sources reviewed.

Qure.ai Quick Facts

Figures marked “reported” come from published reports and may differ between sources; “Not disclosed” means no reliable public figure was found.

What Is Qure.ai?

Qure.ai operates in the Healthcare AI radiology space in India. Understanding a company like this starts with three questions: who is the customer, what painful problem is being solved, and why the solution is better than the alternatives. The sections below apply that lens to Qure.ai.

• Qure.ai makes qER, a head CT triage tool, and qXR, a chest X-ray product that screens for tuberculosis and other abnormalities.
• AI products made up roughly 87% of FY24 revenue, about Rs 123 crore.

The Origin Story of Qure.ai

Every company starts from a noticed gap and a team willing to commit to closing it. Strong origin stories are specific: a clear problem, a founding team with relevant skills, and an early product that real customers could test. Founder-market fit, meaning the team’s lived experience or technical depth in the domain, tends to predict how fast a young company learns.

• Founders: Prashant Warier, Pooja Rao.
• Qure.ai was founded in 2016 by Prashant Warier (CEO) and Dr Pooja Rao, who leads R&D.

Key Milestones and Challenges

No startup grows in a straight line. Early years usually involve slow adoption, product rewrites, hiring mistakes and funding gaps. In the Healthcare AI radiology sector the common turning points are a first paying customer, a regulatory approval, a successful product demonstration or a funding round that lets the team invest ahead of demand. How a team responds to setbacks says more about resilience than any single headline.

• February 2020: reported $16 million round led by Sequoia India.
• June 2020: qER received the company's first US FDA clearance.
• 2022: reported $40 million round led by Novo Holdings and HealthQuad.
• September 2024: reported $65 million Series D led by Lightspeed and 360 ONE Asset.

Qure.ai Funding and Investors

Funding history shows how much outside confidence a company has attracted and how long it can operate before needing more capital. Figures below are reported and may differ between sources; valuation figures are estimates unless the company has confirmed them.

• Reported: $16 million in February 2020 led by Sequoia India, with MassMutual Ventures Southeast Asia.
• Reported: $40 million in 2022 led by Novo Holdings and HealthQuad.
• Reported: $65 million Series D in September 2024 led by Lightspeed and 360 ONE Asset, with Merck Global Health Innovation Fund and Kae Capital participating alongside Novo Holdings, HealthQuad and TeamFund.

How Does Qure.ai Make Money? (Business Model)

A business model describes who pays, how often and how much it costs to serve them. Strong models show repeat usage, improving margins with scale and acquisition channels that do not depend only on paid spend. Weak models show one-off sales, rising costs and growth that stops when spending stops. For companies selling to patients, doctors, hospitals, diagnostic centres, insurers and employers, sales cycles and contract size matter as much as headline growth.

• Revenue is mainly from AI products, which accounted for about 87% of FY24 revenue.

The Numbers: Qure.ai Financials

Financial figures show whether growth is turning into a self-sustaining business. Small and private companies often disclose little, so any number below is included only if it was found in public reporting.

• FY24: reported consolidated revenue of about Rs 141 crore, up 83% from Rs 77 crore in FY23.
• FY24: reported total expenses of about Rs 201 crore, with employee costs of about Rs 108 crore.
• FY24: reported loss of about Rs 48 crore, down about 38.5% from Rs 78 crore.

Market Opportunity for Qure.ai

Market size is easy to exaggerate, so a useful approach separates the total market from the portion a company can realistically reach with its current product and distribution. The main forces behind demand in this sector are rising chronic disease, growing health insurance penetration, government programmes such as Ayushman Bharat and the Ayushman Bharat Digital Mission, and the shift of care to digital and home settings. Each of these widens the opportunity, but capital efficiency and execution decide who captures it.

• Company-stated focus on expansion in the US and Europe.

Technology and Product at Qure.ai

Technology is rarely the whole moat, but it drives speed, cost and customer experience. A practical way to assess it is to separate the capability the company controls from the commodity infrastructure it rents. In this sector the important factors are clinical validity, data quality, integration with hospital and lab systems, and trust among doctors and patients.

• Products apply AI to radiology imaging; the company plans to develop foundational AI models, including GenAI.

Team and Culture at Qure.ai

Teams are the most important and least measurable asset of a young company. Look at how complementary the founders’ skills are, how deep the second layer of leadership is, and how the company hires and retains specialists. Culture shows up in small repeated behaviours: how quickly bad news travels upward and whether commitments to customers are kept.

• Leadership: Prashant Warier, Pooja Rao are named as founders.
• Further detail on the wider team is limited in public sources.

Qure.ai Competitors: Competitive Landscape

A fair competitive analysis names direct rivals, adjacent players who could move into the space, and the customer’s default alternative. Durable advantages include proprietary data or technology, licences and approvals, brand trust, switching costs and cost leadership.

• Direct competitors of Qure.ai vary by product line; a verified rival comparison was not available from public sources.
• What to compare: Product readiness, pricing, customer base, funding runway and regulatory standing.

Risks and Challenges for Qure.ai

• The company remained loss-making in FY24 despite revenue growth.
• Plans include acquisitions and US expansion, which carry execution risk.
• Regulatory risk: medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules.
• Clinical and liability risk: errors in care, diagnosis or product quality can damage trust quickly.
• Data privacy risk: health records are sensitive, and breaches or misuse can bring legal and reputational harm.

Risk is not a reason to avoid a company; it is a reason to price it correctly and to monitor the right indicators over time. Regulation in this sector is shaped by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Qure.ai Growth Outlook: What to Watch

• Reported plans to use Series D funds for US and global expansion, foundational AI model development and medtech acquisitions.
• Key indicators: patient or user volumes, repeat usage, gross margin, clinical outcomes and cost of acquiring each customer.
• Funding position: Whether Qure.ai can reach its next milestone before needing new capital.
• Regulation: Changes from the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Industry Context: Where Qure.ai Fits

India's healthcare market combines a large public system, a fast-growing private hospital sector and an increasingly digital layer. Government initiatives such as Ayushman Bharat and the Ayushman Bharat Digital Mission aim to widen insurance cover and create common digital health records, while telemedicine guidelines and the Digital Personal Data Protection Act shape how digital care and patient data can be used.

Demand is driven by chronic and lifestyle disease, an ageing population, rising insurance penetration and consumers who now expect to book, pay and consult online. Startups in this field compete on trust, clinical quality and convenience, and they must prove outcomes and safety as well as growth.

For readers new to this field, a useful habit is to separate announcements from evidence. A plan, a partnership or a funding headline describes intent, while a delivered product, a paying customer or an audited financial statement describes results. Comparing the two over time shows how reliably a company turns promises into outcomes.

Bull Case and Bear Case for Qure.ai

An investment thesis is a short, testable statement of why a company could become far more valuable, together with what evidence would prove it wrong. The points below are general to this sector and are not forecasts for Qure.ai.

Bull case

• Rising insurance cover and digital adoption expand the customer base.
• Strong clinical evidence builds trust with doctors and hospitals.
• Scale can improve unit economics in diagnostics and care delivery.

Bear case

• Regulatory changes can alter permitted products or business models.
• Customer acquisition costs can erode margins.
• A single safety or privacy incident can damage trust.

Lessons Founders and Investors Can Take from Qure.ai

Studying a company in the Healthcare AI radiology space offers lessons that go beyond any single firm. The points below are general lessons for the sector and are not claims about Qure.ai.

• Trust is the real currency in healthcare, so quality control, clinical evidence and data protection must be built in from the start.
• Distribution through hospitals, clinics, insurers or employers can matter more than a standalone consumer app.
• Unit economics improve when repeat usage replaces expensive one-time customer acquisition.
• Regulatory approvals can take time, so timelines and cash planning should allow for them.
• Integration with existing hospital, lab and records systems reduces friction for adoption.

How to Evaluate Qure.ai as a Startup

• Customer clarity: Can Qure.ai name its customer and the problem it solves in one sentence?
• Evidence of demand: Look for repeat customers, signed contracts or measurable usage rather than announcements alone.
• Economics: Check whether margins improve as volume grows.
• Execution: Compare announced timelines with what has actually been delivered.
• Funding runway: Estimate how long current capital lasts at the present spending rate.
• Regulatory standing: Confirm required approvals are in place.
• Customer concentration: Check whether a few customers account for most of the revenue.
• Management depth: Look for experienced leaders beyond the founders and a stable core team.

The Takeaway

Qure.ai is part of India’s growing Healthcare AI radiology ecosystem. The useful lesson from studying it is the discipline of asking structured questions about customers, economics, advantage and resilience. Companies that answer them well, repeatedly and under pressure are the ones that endure. This article is educational and is not investment advice.

• Clear customers and repeat demand matter more than announcements.
• Regulation and capital needs shape how fast a startup in this sector can grow.
• Track a few leading indicators over time rather than one headline metric.

Qure.ai FAQs: Frequently Asked Questions

What is Qure.ai?

Qure.ai is a healthcare AI startup based in Mumbai, India, that builds AI tools for reading radiology scans such as head CT and chest X-rays for hospitals and clinicians. It is profiled in the Startup Deep Dive series, which explains business model, funding, competitors and risks.

Who founded Qure.ai?

Qure.ai was founded by Prashant Warier, Pooja Rao, and the company reports a founding year of 2016.

How much funding has Qure.ai raised?

No reliable total funding figure is disclosed in the public sources reviewed. Funding figures are reported and may differ between sources, so readers should check the latest company announcements.

How does Qure.ai make money?

Qure.ai earns revenue from its Healthcare AI radiology products and services sold to patients, doctors, hospitals, diagnostic centres, insurers and employers. The exact revenue mix is described in the business model section and is not fully disclosed publicly.

Who are the competitors of Qure.ai?

Competitors of Qure.ai depend on the specific product line. A verified comparison was not available, so see the evaluation checklist above.

What are the main risks for Qure.ai?

Main risks include medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules, funding and capital needs, competition and regulation by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act. This is educational content, not investment advice.

Related Startup Deep Dives: Blue Sky Analytics — short profile of what is publicly known | Brahmaandco Spacetech — short profile of what is publicly known. Browse the full Startup Deep Dive series.

Source

Source: Publicly available data, published reports, industry research, and other credible sources.